MJV 101
Alternative Names: Cancer vaccine - Mojave Therapeutics; Melanoma vaccine-Mojave Therapeutics; MJV-101Latest Information Update: 31 Dec 2021
At a glance
- Originator Mojave Therapeutics
- Class Cancer vaccines
- Mechanism of Action Immunostimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Malignant melanoma
Most Recent Events
- 15 Apr 2003 Data from a media release have been added to the Cancer therapeutic trials section and overview
- 04 Sep 2002 Mojave expects to initiate a phase I/II trial in patients with prostate cancer pending the results of the melanoma trial
- 23 Apr 2002 Phase-I/II clinical trials in Malignant melanoma in USA (unspecified route)